Kestra Medical Technologies (NASDAQ:KMTS) Stock: Insider Elizabeth Kwo Sells 4,010 Shares

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Director Elizabeth Kwo sold 4,010 shares of the stock in a transaction on Monday, September 21st. The shares were sold at an average price of $24.26, for a total value of $97,282.60. Following the completion of the transaction, the director directly owned 14,116 shares in the company, valued at approximately $342,454.16. This trade represents a 22.12% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Up 1.0%

Shares of Kestra Medical Technologies stock opened at $25.76 on Friday. The business has a fifty day simple moving average of $25.17 and a 200 day simple moving average of $22.76. The stock has a market cap of $1.53 billion, a PE ratio of -9.65 and a beta of 0.62. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.33. Kestra Medical Technologies, Ltd. has a 12 month low of $17.34 and a 12 month high of $30.00.

Kestra Medical Technologies (NASDAQ:KMTS) last released its quarterly earnings data on Monday, September 14th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.14). The firm had revenue of $30.97 million for the quarter. Kestra Medical Technologies had a negative return on equity of 63.83% and a negative net margin of 140.43%. Research analysts predict that Kestra Medical Technologies, Ltd. will post -2.45 EPS for the current year.

Hedge Funds Weigh In On Kestra Medical Technologies

Large investors have recently modified their holdings of the business. Quantinno Capital Management LP acquired a new stake in shares of Kestra Medical Technologies in the first quarter valued at about $431,000. California State Teachers Retirement System increased its position in shares of Kestra Medical Technologies by 39.2% during the 1st quarter. California State Teachers Retirement System now owns 27,835 shares of the company’s stock worth $555,000 after purchasing an additional 7,844 shares during the last quarter. Spartan Wealth Advisory Services LLC bought a new stake in shares of Kestra Medical Technologies during the 1st quarter worth approximately $603,000. Bank of New York Mellon Corp raised its stake in shares of Kestra Medical Technologies by 47.2% during the 1st quarter. Bank of New York Mellon Corp now owns 70,113 shares of the company’s stock worth $1,397,000 after purchasing an additional 22,471 shares in the last quarter. Finally, Corient Private Wealth LP boosted its holdings in shares of Kestra Medical Technologies by 284.2% in the 2nd quarter. Corient Private Wealth LP now owns 60,614 shares of the company’s stock valued at $1,542,000 after buying an additional 44,839 shares during the last quarter.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Weiss Ratings upgraded Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, September 16th. BTIG Research reissued a “buy” rating and set a $32.00 target price on shares of Kestra Medical Technologies in a research note on Tuesday, September 15th. Piper Sandler restated an “overweight” rating on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. Wall Street Zen cut shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Saturday, September 12th. Finally, JPMorgan Chase & Co. began coverage on shares of Kestra Medical Technologies in a research report on Monday, August 10th. They set an “overweight” rating and a $30.00 price objective for the company. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Kestra Medical Technologies has an average rating of “Hold” and a consensus price target of $28.38.

Kestra Medical Technologies Company Profile

Kestra Medical Technologies, Inc is a medical device company focused on developing and commercializing technologies for patients at risk of sudden cardiac arrest. The company’s primary product is the ASSURE wearable cardioverter defibrillator, a wearable system designed to continuously monitor a patient’s heart rhythm and deliver an electrical shock when a life-threatening arrhythmia is detected.

The ASSURE system is intended to provide temporary protection for patients who may be at elevated risk of sudden cardiac death but are not yet candidates for, or are awaiting, an implantable cardioverter-defibrillator.